(Q36334926)

English

A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

1 reference

based on heuristic

inferred from title

author name string

Nabil Mubarak

1

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Rabab Gaafar

2

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Samir Shehata

3

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Tarek Hashem

4

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Dani Abigeres

5

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Hamdy A Azim

6

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Gamal El-Husseiny

7

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Hamed Al-Husaini

8

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Zhixin Liu

9

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

language of work or name

0 references

publication date

24 September 2012

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

12

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

423

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477017

30 September 2017

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477017

30 September 2017

Pemetrexed: a review of its use in the management of advanced non-squamous non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477017

30 September 2017

Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477017

30 September 2017

Placebo effects in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477017

30 September 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477017

30 September 2017

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-423

21 January 2018

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-423

21 January 2018

Application of a new multinomial phase II stopping rule using response and early progression.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-423

21 January 2018

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, r

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-423

21 January 2018

Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23006447

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23006447

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-12-423

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36334926&oldid=2198700443"